GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Cyclically Adjusted PB Ratio

Oragenics (Oragenics) Cyclically Adjusted PB Ratio : 0.04 (As of Jun. 08, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Cyclically Adjusted PB Ratio?

As of today (2024-06-08), Oragenics's current share price is $1.67. Oragenics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $41.54. Oragenics's Cyclically Adjusted PB Ratio for today is 0.04.

The historical rank and industry rank for Oragenics's Cyclically Adjusted PB Ratio or its related term are showing as below:

OGEN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.29   Max: 7.6
Current: 0.04

During the past years, Oragenics's highest Cyclically Adjusted PB Ratio was 7.60. The lowest was 0.01. And the median was 0.29.

OGEN's Cyclically Adjusted PB Ratio is ranked better than
94.1% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs OGEN: 0.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oragenics's adjusted book value per share data for the three months ended in Mar. 2024 was $0.230. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $41.54 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oragenics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oragenics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Cyclically Adjusted PB Ratio Chart

Oragenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.36 0.09 0.12

Oragenics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.05 0.12 0.03

Competitive Comparison of Oragenics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oragenics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oragenics's Cyclically Adjusted PB Ratio falls into.



Oragenics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oragenics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.67/41.54
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oragenics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Oragenics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.23/131.7762*131.7762
=0.230

Current CPI (Mar. 2024) = 131.7762.

Oragenics Quarterly Data

Book Value per Share CPI Adj_Book
201406 208.275 100.560 272.930
201409 191.774 100.428 251.636
201412 171.410 99.070 227.999
201503 151.014 99.621 199.757
201506 51.031 100.684 66.790
201509 24.720 100.392 32.448
201512 71.218 99.792 94.044
201603 43.050 100.470 56.464
201606 64.000 101.688 82.937
201609 54.801 101.861 70.895
201612 36.233 101.863 46.873
201703 14.442 102.862 18.502
201706 0.280 103.349 0.357
201709 -2.837 104.136 -3.590
201712 0.073 104.011 0.092
201803 -20.650 105.290 -25.845
201806 -24.078 106.317 -29.844
201809 23.344 106.507 28.883
201812 30.134 105.998 37.462
201903 29.421 107.251 36.149
201906 23.298 108.070 28.409
201909 18.609 108.329 22.637
201912 13.943 108.420 16.947
202003 7.459 108.902 9.026
202006 1.748 108.767 2.118
202009 2.424 109.815 2.909
202012 6.323 109.897 7.582
202103 17.326 111.754 20.430
202106 15.530 114.631 17.853
202109 13.345 115.734 15.195
202112 12.284 117.630 13.761
202203 9.219 121.301 10.015
202206 7.284 125.017 7.678
202209 6.007 125.227 6.321
202212 5.638 125.222 5.933
202303 4.273 127.348 4.422
202306 2.798 128.729 2.864
202309 1.909 129.860 1.937
202312 0.511 129.419 0.520
202403 0.230 131.776 0.230

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oragenics  (AMEX:OGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oragenics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oragenics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics (Oragenics) Business Description

Industry
Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski 10 percent owner
Thomas L Koski 10 percent owner

Oragenics (Oragenics) Headlines

From GuruFocus